Top Markets
Coin of the day
Mallinckrodt plc Mallinckrodt plc

Mallinckrodt plc

MNK
Classificação em ações #30224
Mallinckrodt plc operates as a global pharmaceutical company, engaged in the... Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented into two core divisions: Specialty Brands and Specialty Generics. Under its Specialty Brands arm, Mallinckrodt offers a range of pharmaceuticals for autoimmune and rare diseases, spanning therapeutic areas such as neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. The branded portfolio also encompasses immunotherapy solutions, critical care treatments for neonatal respiratory conditions, pain management drugs, cultured skin substitutes, and gastrointestinal remedies. Key branded products include Acthar Gel, a corticotropin injection prescribed for conditions like rheumatoid arthritis, infantile spasms, and multiple sclerosis; INOmax, a vasodilator used to enhance oxygenation and lessen the need for extracorporeal membrane oxygenation; the Therakos photopheresis platform for immunotherapy; Amitiza, a treatment for constipation; and StrataGraft, designed for adults with deep partial-thickness burns. In its development pipeline, Mallinckrodt is advancing Terlipressin for hepatorenal syndrome and SLN 501, a ribonucleic acid silencing therapeutic. Additionally, through its Specialty Generics segment, the company supplies specialized generic medications and active pharmaceutical ingredients (APIs). Mallinckrodt's branded offerings are marketed to a diverse array of healthcare professionals and institutions, including physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company has also forged a strategic collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference (RNAi) drug targets. Established in 1867, Mallinckrodt plc maintains its headquarters in Dublin, Ireland.
Preço da ação
$0.1
Última sincronização: 2023-09-19
Valor de mercado
$17.68M
Variação (1 dia)
-4.76%
Variação (1 ano)
0.00%
País
IE
Negociar Mallinckrodt plc (MNK)

Categoria

Margem Operacional de Mallinckrodt plc (MNK)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Mallinckrodt plc, a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Mallinckrodt plc de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -
IN
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.